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A B S T R A C T  
Since a year ago, pandemic covid 19 has entered Indonesia, and efforts to reduce and control have been carried out several programs, one 
of which is vaccination. The ideal projection is two direct strategies: hybrid distribution that combines active outreach into priority groups with 
passive distribution to the general public and single-dose distribution to as many populations as possible. The previous plan was to save a 
second dose as a backup. The proper fulfillment of vaccination needs in each population required to achieve herd immunity to stop the spread 
of the virus will vary, depending on the variant of the virus in circulation and the heterogeneous level of that population, also depending on 
the density and mobility of the population. In addition, the duration of protection provided by natural immunity and vaccine-induced immunity 
is not well established, and different vaccines can provide different durations and degrees of humoral and cellular immunity. 
INTRODUCTION 
Since a year ago, the covid 19 pandemics has entered In-
donesia, and efforts to reduce and control have been car-
ried out several programs, one of which is vaccination. Af-
ter going through phase III clinical trials, Worl Health Or-
ganization (WHO) said the Sinovac vaccine has efficacy 
values to prevent 51 percent of symptomatic COVID-19 
cases in people aged 18 years and over. At the same time, 
research conducted in Indonesia found that the efficacy of 
the Sinovac vaccine reached about 65 percent. Vaccines 
can also prevent potential hospitalization cases by up to 
100 percent in the vaccine-receiving population.1 
 
So far, millions of vaccine doses have been given to the 
public to achieve the met target of 70% of the population 
being vaccinated to form herd immunity. Vaccination is pri-
oritized for those at high risks, such as the elderly, health 
workers, and people with chronic diseases such as heart 
disease, cancer, and diabetes.2 The development of  vac-
cination on  25  Juli2021, about 27.3%of the world's popu-
lation has been vaccinated the first   dose,  but  people in 
low-income countries    only  1.1% and Indonesia has ob-
tained breast  milk vaccines much as  16.26%, with details 
that have received complete vaccination  6.55% and first 
vaccination 9.71%.3 
 
Referring to the achievement of national vaccination ob-
tained data until July 25, 2021, it takes as long as 162 days 
to achieve vaccination coverage of 16.26%; then, it takes 
an additional 521 days (1.5 years) if you want to reach the 
target of 70% with a normal vaccination rhythm. The Indo-
nesian government needs to accelerate vaccination more 
massively. However, given the number of international 
vaccine production that is experiencing constraints will 
have an impact on the potential to increase the number of 
high-risk communities for exposure. Protection and pre-
vention measures against immediate transmission should 
be taken to anticipate the high rate of virus reproduction 
by strengthening 5M (Mask, Handwashing, physical dis-
tancing, avoiding crowds, and reducing mobility). 
 
The reproductive rate (R0) of the virus is very high: 2.24–
3.58 to 72 hours or more on the surface of an object. If this 
occurs in people over the age of fifty-five and people with 
chronic diseases at risk, it is greater to experience the se-
verity of even.4 A variant of the virus falls into the VOI cat-
egory (Varians of Interest) known as delta. Varian Delta is 
predicted to be 40 percent more contagious than the Alpha 
variant. One person infected with the Delta variant can 
transmit the same virus to 7-8 others. The emergence of 
the delta variant (B.1617.2) has spread very quickly. Some 
countries are protecting with vaccinations, one of which is 
Pfizer's vaccine. Vaccine BNT162b2(Pfizer), the effective-
ness of two doses is 93.7% (95% CI, 91.6 to 95.3) among 
people with alpha variants and 88.0% (95% CI, 85.3 to 
90.1) among those with delta variants. With the ChAdOx1 
nCoV-19 vaccine, the effectiveness of two doses was 
74.5% (95% CI, 68.4 to 79.4) among people with alpha 
and 67.0% (95% CI, 61.3 to 71.8) variants among those 
with delta variants.5 
CHALLENGES OF VACCINATION PROGRAM 
Single-dose (82%) is expected to save more lives than us-
ing two doses since the first vaccine injection in extensive 
SUPRIYADI / MEDISAINS - VOL. 19 NO. 2 (2021) 25-28 
26 
coverage provides a greater level of protection in the pop-
ulation than complete vaccination. Although first-dose 
campaigns can speed up group immunity and require far 
fewer resources than 2-dose campaigns, it is worth being 
careful that additional data and single-dose trials are 
needed to establish efficacy. If the efficacy of a single dose 
< 82%, then the difference between a single-dose strategy 
and a 2-dose strategy becomes smaller—the same rate in 
mortality rates from both strategies when single-dose effi-
cacy was 52%. Vaccines with low efficacy may increase 
the risk of resistance to the new variant.6,7 May be a polit-
ical, commercial, and social role in shifting priorities during 
vaccination campaigns.8 The overestimation that vaccines 
provide lasting immunity and prevent fatal infections or 
symptoms, pandemic fatigue, or overconfidence in vac-
cination campaigns triggers risky behaviors that cause 
cases to surge toward the peak of pandemics in the ab-
sence of effective mitigation. The effect of vaccine benefits 
on public health begins to decrease when there is a high 
and rapid rate of COVID-19 transmission, looser mitigation 
measures, lower immunity levels before the emergence of 
the more contagious SARS-CoV-2 variant.   
 
Risk is an approach to maximizing the vaccine's effects, 
but not at the expense of vaccination speed. The ideal pro-
jection is two direct strategies: a hybrid distribution that 
combines active outreach to priority groups with passive 
distribution to the general public and a single-dose distri-
bution to as many populations as possible, a previous plan 
to keep a second dose as a backup. 
 
The indecision of the COVID-19 vaccine has become an 
emerging problem in some countries. According to the lat-
est estimates from the survey, some developing countries 
such as India report a higher willingness to vaccinate. 
However, other countries such as Serbia, Croatia, France, 
Lebanon, and Paraguay are lower in the 10th acceptance 
spectrum.9 In Indonesia, about 65% of respondents said 
they were willing to accept the COVID-19 vaccine is pro-
vided by the Government, while eight percent of them re-
fused. The remaining 27% expressed doubts about the 
Government's plan to distribute the COVID-19 vaccine are 
several issues that contribute to the indecision of the 
COVID-19 vaccine. In many countries, vaccines have 
been bought or developed so quickly that it raises con-
cerns that trials are being accelerated and regulatory 
standards are loosened. Another concern is that pandem-
ics led to the use of the first mRNA vaccine. The novelty of 
the approach alone has sparked some doubts. Many peo-
ple have little faith in manufacturing companies. There is 
also an ongoing disinformation campaign against the 
COVID-19 vaccine on various social media platforms. For 
developing countries, concerns about the composition of 
vaccines and their acceptance of religious and ethnic 
groups are widely present.  
 
The safety of vaccines is also in question. The critical role 
of AstraZeneca Oxford's vaccine was effectively under-
mined when scientists began reporting cases of throm-
bosis.10 rials for the vector-based vaccine Adenovirus 26, 
produced by Johnson &Johnson, were also delayed when 
one of the participants developed an unexplained. This 
puts underdeveloped countries at significant risk because 
the most viable and cost-effective options are no longer 
available. According to a recent survey, certain factors are 
presented as predictors of receiving the COVID-19 vac-
cination. The most important predictor was the vaccination 
of participants against Covid-19. The acceptance of more 
health workers as part of the team working in the COVID-
19 unit is vital. The income factors of people affected by 
the economic crisis are more receptive to the idea of vac-
cination. Interestingly, age is not a vital factorof.11 
 
The fulfillment of the proper vaccination needs in each 
population needed to achieve herd immunity to stop the 
spread of the virus will vary, depending on the variant of 
the virus in circulation, as well as the heterogeneous level 
of that population, also depending on the density and mo-
bility of the population. In addition, the duration of protec-
tion provided by natural immunity and vaccine-induced im-
munity is not well established, and different vaccines can 
provide different durations and degrees of humoral (B cell) 
and cellular (T cell) immunity.12,13 It is also unknown how 
long and effective immunity is given by mixed vaccines 
and third dose boosters in different populations, including 
different ethnicities. Finally, children who still have not 
been routinely vaccinated because most COVID-19 vac-
cines have not been licensed for this subgroup, especially 
elementary school children, meaning they will remain 
largely vulnerable populations where the group's immunity 
levels are uncertain. Therefore, the exact level of popula-
tion immunity to 'end' pandemics in every country and 
globally is difficult to determine.14 
 
Effective herd immunity has complicated consequences in 
SARS-CoV-2 infection. There are various factors and sev-
eral obstacles that must be solved to achieve them. Group 
immunity in many regions and geographical locations is 
difficult to achieve simultaneously due to large population 
numbers and social differences. Based mathematics 
shows that 50-66% of the population needs to be immun-
ized naturally or artificially, and this percentage is not eas-
ily achieved. Another problem that science must establish 
is the duration of this herd immunity. It is still unknown for 
SARS-CoV2 infection how long immune memory lasts. An 
efficient immune response cannot be performed in all indi-
viduals, and relapsing cases have been widely reported. 
An effective vaccine is likely to control current outbreaks 
and induce group immunity to prevent future outbreaks, 
but also strengthening the immune system is a way to al-
leviate the health care system. In addition, community tac-
tics in the face of lockout need to be thoroughly elaborated 
so that the economic impact must be minimized and the 
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formation of solid herd immunity in this infection will be op-
timal.15 The results showed that antiviral antibodies in pa-
tients recovering against SARS-CoV-2 did not decrease 
within four months of diagnosis. We estimate that the risk 
of death from infection is 0.3% and that 44% of people in-
fected with SARS-CoV-2 are not diagnosed with qPCR.16 
STRATEGIES AND SCENARIOS 
Therefore, dealing with this pandemic needs to be done 
correctly and well. There are at least four strategies there 
are scenarios that can be done, among others: Without 
vaccines (scenario 1), the spread of COVID-19 can be 
suppressed in areas by maintaining strict social distance 
measures and levels of face mask use. However, loosen-
ing social distance restrictions to pre-pandemic levels 
without changing the current use of face masks will lead to 
a new COVID-19 outbreak, resulting in 0.8–4 million infec-
tions and 15,000–100,000deaths over 16 months. In these 
circumstances, introducing a vaccine (scenario 2) would 
partially offset this negative impact, albeit with relatively 
low vaccine effectiveness and coverage. However, if face 
masks are reduced by up to 50% (scenario 3), a vaccine 
that is only 50% effective (weak vaccine) will require 55-
94% coverage to suppress the epidemic. Vaccines that are 
80% effective (moderate vaccines) require only 32-57% 
coverage to suppress epidemics. 
 
Conversely, if the use of masks is stopped completely 
(scenario 4), a weak vaccine will not suppress the epi-
demic, and further significant outbreaks will occur. A mod-
erate vaccine with 48-78% coverage or a firm (100% ef-
fective) vaccine with 33-58% coverage would be needed 
to suppress the epidemic. Delaying the rollout of vaccina-
tions for 1-2 months will not substantially change the epi-
demic trend if current non-pharmaceutical interventions 
are maintained. A moderate vaccine with 48-78% cover-
age or a firm (100% effective) vaccine with 33-58% cover-
age would be needed to suppress the epidemic. Delaying 
the rollout of vaccinations for 1-2 months will not substan-
tially change the epidemic trend if current non-pharmaceu-
tical interventions are maintained. A moderate vaccine 
with 48-78% coverage or a firm (100% effective) vaccine 
with 33-58% coverage would be needed to suppress the 
epidemic. Delaying the rollout of vaccinations for 1-2 
months will not substantially change the epidemic trend if 
current non-pharmaceutical interventions are maintained. 
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